I

Imexpharm Corp
VN:IMP

Watchlist Manager
Imexpharm Corp
VN:IMP
Watchlist
Price: 48 050 VND -0.93%
Market Cap: 7.4T VND
Have any thoughts about
Imexpharm Corp?
Write Note

EV/EBIT
Enterprise Value to EBIT

21.6
Current
7
Median
16.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
21.6
=
Enterprise Value
7.2T VND
/
EBIT
335.4B VND
All Countries
Close
Market Cap EV/EBIT
VN
Imexpharm Corp
VN:IMP
7.4T VND 21.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
755.8B USD 54.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 23
US
Johnson & Johnson
NYSE:JNJ
351.1B USD 15.1
US
Merck & Co Inc
NYSE:MRK
251.8B USD 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 16
EBIT Growth EV/EBIT to Growth
VN
I
Imexpharm Corp
VN:IMP
Average EV/EBIT: 1 812.3
21.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.1
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15.1
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
18.1
2-Years Forward
EV/EBIT
15.7
3-Years Forward
EV/EBIT
N/A

See Also

Discover More